| AstraZeneca49 programs in shared conditions | 21 · 12 with both in phase 3Atherosclerosis, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung +18 | benralizumab, tezepelumab, BFF MDI +6 | - Eli Lilly and Company’s pirtobrutinib vs acalabrutinib (US & EU rights: AstraZeneca) (Lymphoma, B-Cell, NCT04662255)
- AstraZeneca’s saruparib in a combination vs abemaciclib (US & EU rights: Eli Lilly and Company) (Breast Neoplasms, NCT06380751)
- AstraZeneca’s camizestrant added to abemaciclib (US & EU rights: Eli Lilly and Company) (Breast Neoplasms, NCT06380751)
- and 9 more
|
| AbbVie24 programs in shared conditions | 18 · 5 with both in phase 3Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative, Crohn Disease +15 | upadacitinib, risankizumab, telisotuzumab adizutecan +4 | - AbbVie’s telisotuzumab adizutecan vs Ramucirumab (US & EU rights: Eli Lilly and Company) (Carcinoma, Non-Small-Cell Lung, NCT07821684)
- Eli Lilly and Company’s pirtobrutinib vs ibrutinib (US rights: AbbVie) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT05254743)
- Eli Lilly and Company’s pirtobrutinib vs ibrutinib (US rights: AbbVie) (Lymphoma, B-Cell, NCT04662255)
- and 3 more
|
| Novo Nordisk A/S29 programs in shared conditions | 8 · 5 with both in phase 3Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 +5 | zenagamtide, insulin icodec, Semaglutide +2 | - Eli Lilly and Company’s retatrutide vs Semaglutide (US & EU rights: Novo Nordisk A/S) (Diabetes Mellitus, NCT06982859)
- Eli Lilly and Company’s retatrutide vs Semaglutide (US & EU rights: Novo Nordisk A/S) (Diabetes Mellitus, Type 2, NCT06260722)
- Eli Lilly and Company’s LY4057996 in a combination vs insulin degludec (US & EU rights: Novo Nordisk A/S) (Diabetes Mellitus, Type 1, NCT06945406)
- and 2 more
|
| Johnson & Johnson18 programs in shared conditions | 13 · 5 with both in phase 3Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative, Crohn Disease +10 | guselkumab, icotrokinra, lazertinib +4 | - Eli Lilly and Company’s pirtobrutinib vs ibrutinib (EU rights: Johnson & Johnson) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT05254743)
- Eli Lilly and Company’s pirtobrutinib vs ibrutinib (EU rights: Johnson & Johnson) (Lymphoma, B-Cell, NCT04662255)
- Johnson & Johnson’s amivantamab in a combination vs Cetuximab (US rights: Eli Lilly and Company) (Colorectal Neoplasms, NCT06750094)
- and 1 more
|
| Hoffmann-La Roche25 programs in shared conditions | 16 · 7 with both in phase 3Alzheimer Disease, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung +13 | trontinemab, inavolisib, giredestrant +6 | - Hoffmann-La Roche’s enicepatide vs Tirzepatide (US & EU rights: Eli Lilly and Company) (Diabetes Mellitus, Type 2, NCT07889648)
- Hoffmann-La Roche’s inavolisib added to abemaciclib (US & EU rights: Eli Lilly and Company) (Breast Neoplasms, NCT03424005)
- Hoffmann-La Roche’s vustanaciclib in a combination vs abemaciclib (US & EU rights: Eli Lilly and Company) (Breast Neoplasms, NCT07100106)
- and 2 more
|